The collaboration reflects the growing importance of precision diagnostics in oncology drug development, where biomarker-driven approaches are increasingly essential for identifying appropriate patient populations, improving trial efficiency, and supporting regulatory approvals.

As key components of the collaboration, Guardant Health and Nuvalent plan to:

  • Utilize Guardant's portfolio of tissue and liquid biopsy tests to support certain Nuvalent global clinical studies;
  • Evaluate opportunities to develop Guardant tissue and/or liquid biopsy assays as companion diagnostics (CDx) to support potential regulatory approvals of Nuvalent's current investigational candidates; and,
  • Collaborate on the global commercialization of Nuvalent's product candidates, if approved, and Guardant companion diagnostics across major global key markets.